Home > ASME Articles > Gender Differences in Individuals with Opioid Use Disorder Receiving Inpatient Care
This analysis looked at baseline gender differences in individuals participating in the NIDA Clinical Trials Study CTN-0051 (X:BOT), a randomized, controlled trial in the NIDA Clinical Trials Network comparing extended-release naltrexone to buprenorphine (CTN-0051, the X:BOT study). Participants (N=570) provided demographic, substance use, and psychiatric history information.
Women in the study, compared to men, were:
- significantly younger;
- more likely to identify as bisexual, live with a sexual partner, and be financially dependent on someone else;
- less likely to be employed;
- more likely to report psychiatric history (anxiety/panic disorder, bipolar disorder, major depression);
- more likely to engage in sexual and drug risk behaviors (exchanging sex for drugs, sharing injection equipment).
Women also reported shorter duration of opioid use, but similar age of onset.
Conclusions: Findings underscore economic, psychiatric, and infection vulnerability among women with OUD, which may complicate treatment initiation, retention, and recovery. Gender-specific interventions focused on these areas of disparity for women with OUD should be considered, including integration of OUD care with treatment for co-occurring psychiatric disorders and trauma, couples-based risk reduction interventions that address relationship dynamics, and interventions that address the unique needs of sexual minority women.
Find it in the CTN Library